Form 8-K - Current report:
SEC Accession No. 0001193125-25-134913
Filing Date
2025-06-04
Accepted
2025-06-04 16:18:35
Documents
18
Period of Report
2025-06-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d34558d8k.htm   iXBRL 8-K 35850
2 EX-1.1 d34558dex11.htm EX-1.1 208667
3 EX-5.1 d34558dex51.htm EX-5.1 10327
4 EX-99.1 d34558dex991.htm EX-99.1 8666
8 GRAPHIC g34558g0604120404644.jpg GRAPHIC 2021
9 GRAPHIC g34558g0604120419079.jpg GRAPHIC 4545
10 GRAPHIC g34558g0604135950806.jpg GRAPHIC 5328
  Complete submission text file 0001193125-25-134913.txt   460895

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA trvi-20250603.xsd EX-101.SCH 2880
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20250603_lab.xml EX-101.LAB 17994
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20250603_pre.xml EX-101.PRE 11281
20 EXTRACTED XBRL INSTANCE DOCUMENT d34558d8k_htm.xml XML 3639
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 251023340
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)